RxSight price target raised to $75 from $64 at Needham

Needham analyst David Saxon raised the firm’s price target on RxSight to $75 from $64 and keeps a Buy rating on the shares. The company reported “another beat and raise” in Q1 on both revenue and gross margins, the analyst tells investors in a research note. The firm believes RxSight should continue to see adoption of its platform, resulting in “strong durable revenue growth.” It expects further upside to revenue and increasing visibility to operating income profitability over the next couple of years.